2024-03-28T09:02:51Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_CBD0E5E6E601
2024-03-23T02:59:10Z
serval:BIB_CBD0E5E6E601
MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
10.1093/neuonc/noab087
000718357900019
33825892
Frappaz
D.
author
Barritault
M.
author
Montané
L.
author
Laigle-Donadey
F.
author
Chinot
O.
author
Le Rhun
E.
author
Bonneville-Levard
A.
author
Hottinger
A.F.
author
Meyronnet
D.
author
Bidaux
A.S.
author
Garin
G.
author
Pérol
D.
author
article
review
2021-11-02
Neuro-oncology
1523-5866
1522-8517
journal
23
11
1949-1960
Anilides/therapeutic use
Cerebellar Neoplasms/drug therapy
Cerebellar Neoplasms/genetics
Hedgehog Proteins/antagonists & inhibitors
Hedgehog Proteins/genetics
Humans
Medulloblastoma/drug therapy
Medulloblastoma/genetics
Pyridines/therapeutic use
Temozolomide/therapeutic use
SHH pathway
SMO inhibition
medulloblastoma
eng
60_published
peer-reviewed
Publication types: Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish